SARS-CoV-2 and other corona viruses use ACE2 on the surface of human cells as an entry point for respiratory tract infections. The viral spike-1 protein binds to ACE2 on the surface of the target cells. After docking, the virus is taken up into the cell.
Laboratory studies showed that the addition of soluble ACE2 blocked the coronaviruses SARS-Cov-2 and SARS-CoV, preventing infection of cells. ACE2 also has a natural enzyme activity in the cardiovascular system that provides potential protection for the lungs, heart and kidney from threatening organ failure. Formycon has therefore combined the human ACE2 protein to the constant part of human antibodies (IgG4-FC) by using computer-assisted structural design, creating a highly effective SARS-CoV-2 blocker with enzymatic activity (FYB207).
In vitro tests show that FYB207 completely prevents infection of the cells, while preserving natural enzyme activity. Due to its design, the FYB207 compound provides maximum protection against virus escape by mutation compared to vaccines and neutralizing antibodies.